

## New pharma partner to deliver solutions from idea to registration and beyond

Please call

Klaus Snej Jensen  
CEO

P +45 7177 2547  
M [ksj@hb-medical.dk](mailto:ksj@hb-medical.dk)

Susanne  
Ølsgaard Felumb  
Vice President  
Regulatory Affairs and  
Pharmacovigilance

P +45 4450 3206  
M [sof@pharmadvice.dk](mailto:sof@pharmadvice.dk)

*Two experienced partners — HB Medical Hørsholm and PharmAdvice — join forces and form NORD Pharma Partners to deliver innovative, safe and accessible pharma solutions to clients in the Nordic countries and Europe.*

“We want to help our clients achieving their goals in a faster and better way” says CEO Klaus Snej Jensen. “Many of our clients are small to medium sized pharma businesses and start ups and they don’t have the required services in-house. With our joined competence we now have the range of services and flexibility to support them all the way from idea to registration.”

The two companies have been working together for many years and see the merger as a natural next step. “It has always been important to both companies to know our clients really well and deliver a very customized and personal service” says Susanne Ølsgaard Felumb, Vice President, Regulatory Affairs and Pharmacovigilance. “We both believe in forming close relations and being accessible and thereby making a difference for our clients.”

NORD Pharma Partners provides innovative, safe and accessible solutions to the pharma industry. We advise and contribute to all phases - from idea to registration and lifecycle management. NORD Pharma Partners offers high quality services within contract manufacturing, clinical trial supply, regulatory affairs, pharmacovigilance and GMP. The new company will be located in DTU Science Park in Hørsholm.

“We are here to shorten the time to market for our customers and we believe that strong and close collaboration is key to achieving this. When each of us does what we do best and together, then we can deliver tomorrow’s pharma solutions and the results that our clients demand.” says Klaus Snej Jensen.